DDInter101 DDInter635
Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors.
Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents. Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. Ltd. and co-developed with Roche and Genentech.
Anti-inhibitor coagulant complex {u} may lead to a major life threatening interaction when taken with {v} Tranexamic acid
Anti-inhibitor coagulant complex may lead to a major life threatening interaction when taken with Tranexamic acid